HomeSearch for 'High'

High - News and Articles about commonly prescribed drugs

HPTN 075 research reveals excessive threat of HIV an infection amongst MSM and TGW in sub-Saharan Africa

Posted in News on 26th October 2018

Researchers from the HIV Prevention Trials Community (HPTN) in the present day offered outcomes from the HPTN 075 Examine on the HIV Analysis for Prevention (HIVR4P) convention in Madrid, Spain. The research evaluated the feasibility of HIV prevention analysis amongst males who’ve intercourse with males (MSM) and transgender ladies (TGW) in three nations in sub-Saharan Africa. Findings from the research confirmed individuals have been at an alarming threat for getting HIV. The incidence amongst research individuals was considerably increased than the estimated incidence amongst heterosexual women and men within the common inhabitants in the identical nations.

“A number of research have proven the burden of HIV is sort of excessive amongst MSM and TGW, however little is thought in regards to the charge of recent infections, or HIV incidence, amongst these teams in sub-Saharan Africa,” mentioned Theo Sandfort, PhD, HPTN 075 protocol chair and analysis scientist, HIV Heart for Scientific and Behavioral Research on the New York State Psychiatric Institute and Columbia College in New York. “The exceptionally excessive HIV incidence we discovered signifies an pressing want for elevated entry to HIV prevention approaches that think about all of the components that put this weak inhabitants at such excessive threat.”

A complete of 401 MSM and TGW, no matter HIV an infection standing, have been enrolled at 4 websites in Kenya, Malawi and South Africa. Every participant was adopted for 12 months, throughout which 5 research visits have been carried out. These visits included interviewing individuals about behaviors that will put them in danger for HIV an infection, medical examinations and assortment of blood samples. Of the 401 enrolled, 329 have been HIV-negative on the time of enrollment. By the top of the research, 21 of them had turn into contaminated with HIV. This interprets to an total incidence charge of 6.96 per 100 person-years. Incidence charges differed considerably by research website: Malawi: 1.three; Kenya: three.75; Soweto, South Africa: eight.97; and Cape City, South Africa: 14.44.

“HPTN 075 gives compelling findings that point out an pressing want for additional HIV prevention research for males who’ve intercourse with males and transgender ladies in sub-Saharan Africa,” mentioned Wafaa El-Sadr MD, MPH, MPA, HPTN co-principal investigator and professor of epidemiology and drugs at Columbia College in New York. “These research should study the realities by which these teams exist and develop built-in intervention methods which can be efficient and possible.”

“MSM and TGW in sub-Saharan Africa face distinct structural obstacles to accessing HIV prevention and therapy,” mentioned Myron Cohen, MD, HPTN co-principal investigator and director of the College of North Carolina at Chapel Hill Institute for World Well being and Infectious Illnesses in Chapel Hill, NC. “The HPTN is poised to deal with these obstacles as we prioritize this inhabitants in our prevention agenda.”

Supply:

https://www.hptn.org/news-and-events/press-releases/hptn-075-study-demonstrates-high-rate-of-hiv-infection-among-african

Neoadjuvant medical trial of immune checkpoint blockade for melanoma sufferers yields excessive response fee

Posted in News on 9th October 2018

Mixture checkpoint blockade earlier than surgical procedure (neoadjuvant remedy) produced a excessive response fee amongst sufferers with high-risk stage three melanoma, with practically half having no signal of illness at surgical procedure, however a excessive incidence of uncomfortable side effects induced the trial to be closed early.

The part II research was led by researchers at The College of Texas MD Anderson Most cancers Middle. Outcomes of the research, the primary randomized neoadjuvant medical trial of immune checkpoint blockade for melanoma sufferers, are reported in Nature Medication.

Sufferers obtained both the PD-1 inhibitor nivolumab or the mixture of nivolumab and the CTLA-Four checkpoint inhibitor ipilimumab. Every drug blocks a separate off-switch on T cells, liberating the immune system to assault most cancers. All sufferers obtained nivolumab after surgical procedure.

On the mixture arm, eight of 11 (73 %) sufferers had their tumors shrink, 5 (45 %) had no proof of illness at surgical procedure (pathological full response), and 73 % had grade three uncomfortable side effects, inflicting dose delays in 64 % and delaying surgical procedure for some. There have been no grade Four uncomfortable side effects.

Within the nivolumab arm, three of 12 (25 %) had their tumors shrink and had pathological full response, solely eight % had grade three uncomfortable side effects. Two sufferers progressed to stage Four metastatic illness earlier than they might get to surgical procedure.

“On this trial, therapy with single-agent anti-PD-1 was related to modest response charges, and we have been involved that two sufferers on that arm progressed and couldn’t go to surgical procedure,” stated co-first creator Rodabe Amaria, M.D., assistant professor of Melanoma Medical Oncology. “Therapy with mixed checkpoint blockade was rather more efficient, however on the expense of serious toxicity. It’s clear from this trial that we have to additional optimize this therapy method.”

All of those that achieved pathological full response in both arm stay with out proof of illness recurrence. Total survival was 100 % at 24 months within the mixture arm and 75 % within the nivolumab arm.

“The benefit of a neoadjuvant method on this setting is that it allows an interval analysis of the tumor cells after remedy to find out the extent to which these tumor cells responded to the remedy in actual time and predict which sufferers are more likely to expertise sturdy responses going ahead. It additionally gives us the tissue sources to find out why tumors could not reply to remedy and thus tailor therapies going ahead as we be taught extra about resistance,” stated co-senior creator on the research, Michael Tetzlaff, M.D. Ph.D., affiliate professor of Pathology and Translational and Molecular Pathology.

Checkpoint blockade has been efficient towards metastatic melanoma and in lowering the danger of relapse after surgical procedure for high-risk stage three illness. Nonetheless, there may be proof in preclinical fashions that therapy earlier than surgical procedure could also be superior to giving these brokers within the adjuvant setting (after surgical procedure).

Amaria and senior creator Jennifer Wargo, M.D., affiliate professor of Surgical Oncology and Genomic Medication, launched the investigator-initiated trial via MD Anderson’s Moon Pictures Program™, a collaborative effort to speed up the event of scientific discoveries into medical advances that save sufferers’ lives.

Because of the outcomes of this research, the staff re-designed the research to discover the security and efficacy of nivolumab plus relatlimab, an inhibitor of the LAG3 immune checkpoint, a mix that Amaria notes thinks could also be more practical than nivolumab alone with a greater aspect impact profile than therapy with mixed CTLA-Four and PD-1 blockade.

Figuring out biomarkers of response and resistance

“This presurgical platform gives a perfect setting to check biomarkers of response, mechanisms of resistance, and differential results of those two generally used therapy regimens,” stated co-first creator Sangeetha Reddy, M.D., teacher in Most cancers Medication. “On this research we confirmed recognized biomarkers of response and noticed novel biomarkers of therapeutic response that we at the moment are learning additional”.

Evaluation of biopsies and blood samples taken at a number of time factors through the trial revealed:

  • Baseline infiltration of tumors by lymphoid cells and complete mutational burden have been related to response to remedy.
  • Early on-treatment biopsies have been higher predictive of who would reply to each therapies in comparison with baseline biopsies.
  • Molecular analyses utilizing a novel spatial profiling know-how recognized differential abundance of a number of immune markers that correlated with response and/or resistance to neoadjuvant immune checkpoint blockade.
  • T cell receptor sequencing recognized differential patterns in responders versus non-responders to anti-PD-1 remedy versus mixed CTLA-Four and PD-1 blockade. Responders to PD-1 monotherapy confirmed proof of a pre-existing however inhibited T cell repertoire that additional expanded throughout therapy, whereas therapy with mixture remedy was related to extra variable adjustments within the T cell repertoire.

This trial was carried out in parallel to a trial co-led by Christian Clean, M.D., Ph.D., and Ton Schumacher, Ph.D. of the Netherlands Most cancers Institute – who examined using neoadjuvant versus adjuvant (post-surgical) therapy with mixed CTLA-Four and PD-1 blockade in an identical affected person inhabitants.

“The findings of their trial are provocative, demonstrating larger variety of tumor-resident TCRs expanded within the peripheral blood of sufferers receiving neoadjuvant versus adjuvant checkpoint blockade – supportive of what was seen in preclinical fashions – and means that the neoadjuvant method could also be superior.” Wargo stated.

This MD Anderson-led staff is now working with others worldwide in a global neoadjuvant melanoma consortium to harmonize these efforts.

Supply:

https://www.mdanderson.org/newsroom/2018/10/neoadjuvant-combination-checkpoint-blockade-trial-yields-high-response-rates-for-melanoma-patients.html

Genentech pronounces Section III examine outcomes of baloxavir marboxil in folks at excessive threat of flu

Posted in News on 7th October 2018

Genentech, a member of the Roche Group, as we speak introduced that the Section III CAPSTONE-2 examine confirmed therapy with baloxavir marboxil considerably diminished the time to enchancment of influenza signs versus placebo (median time of 73.2 hours versus 102.three hours; p<zero.0001) in folks at excessive threat of significant issues from the flu, which incorporates adults 65 years of age or older, or those that have situations similar to bronchial asthma, continual lung illness, morbid weight problems, or coronary heart illness. Baloxavir marboxil was well-tolerated and no new security alerts have been recognized. Outcomes of the examine might be introduced as a late-breaking oral presentation throughout IDWeek 2018 in San Francisco, California on Saturday, October 6, 2018 (Summary #LB16). Baloxavir marboxil was found and developed by Shionogi & Co., Ltd., and is offered in Japan beneath the commerce title Xofluza®.

“That is the primary Section III trial to reveal a major, clinically significant profit in folks at excessive threat for issues from the flu for which there aren’t any at the moment authorised medicines,” stated Sandra Horning, M.D., chief medical officer and head of World Product Growth. “This examine provides to the rising physique of proof supporting baloxavir marboxil as a possible first-in-class antiviral flu therapy, and we plan to debate these information with well being authorities all over the world.”

The CAPSTONE-2 examine additionally confirmed that baloxavir marboxil demonstrated efficacy (diminished time to enchancment of influenza signs) in influenza sort A/H3N2 (median time of 75.four hours and 100.four hours; p<zero.05) and kind B (median time of 74.6 hours and 100.6 hours; p<zero.05) versus placebo. As well as, outcomes for the general affected person inhabitants of the examine confirmed numerically shorter time to enchancment of influenza signs of baloxavir marboxil versus oseltamivir with a median time to enchancment of signs of 73.2 hours for baloxavir marboxil in contrast with 81.zero hours for oseltamivir (p=zero.8347). Within the subpopulation of individuals with influenza sort B, a subgroup the place some antiviral therapies have proven solely restricted efficacy or inconclusive information, baloxavir marboxil was considerably extra efficacious than oseltamivir in decreasing the time to enchancment of signs (median time of 74.6 hours versus 101.6 hours; p<zero.05).

Baloxavir marboxil demonstrated efficacy in comparison with placebo and oseltamivir for key secondary endpoints, together with decreasing the time that the virus continued to be launched from the physique (viral shedding; median time of 48.zero hours for baloxavir marboxil versus 96.zero hours for each placebo and oseltamivir; p<zero.0001). Baloxavir marboxil additionally diminished using antibiotics and incidence of influenza-related issues (three.four p.c and a couple of.eight p.c respectively) in comparison with placebo (7.5 p.c and 10.four p.c; p=zero.01 and p<zero.05). Baloxavir marboxil had a numerically decrease general incidence of reported hostile occasions (25.1 p.c) in contrast with placebo (29.7 p.c) or oseltamivir (28.zero p.c).

Baloxavir marboxil is a single-dose, investigational oral drugs that represents the primary of a brand new class of antivirals with a novel proposed mechanism of motion that differs from different at the moment obtainable therapies. Baloxavir marboxil has already demonstrated a clinically vital profit over placebo in in any other case wholesome folks with influenza within the Section III CAPSTONE-1 examine. The U.S. Meals and Drug Administration (FDA) accepted a New Drug Utility (NDA) and granted Precedence Evaluation to baloxavir marboxil as a single-dose, oral therapy for acute, uncomplicated influenza in folks 12 years and older primarily based on the outcomes from CAPSTONE-1 and an earlier Section II examine. The FDA is anticipated to decide on approval by December 24, 2018. If authorised, baloxavir marboxil would be the first single-dose oral antiviral, and the primary drugs with a novel proposed mechanism of motion to deal with the flu in practically 20 years.

Genentech additionally introduced that they’ve entered right into a private-public partnership with the Biomedical Superior Analysis and Growth Authority (BARDA) of the U.S. Division of Well being and Human Providers (HSS), to advance the event of medicines for infectious ailments for which there’s a major unmet want. As a part of the settlement, BARDA will present funding that may help the event of baloxavir marboxil for severely unwell hospitalized folks with influenza, with the potential for funding of different research.

Supply:

https://www.gene.com/media/press-releases/14751/2018-10-03/positive-phase-iii-results-for-baloxavir

Research utilizing DFMO reveals optimistic outcomes for youngsters with excessive danger neuroblastoma

Posted in News on 2nd October 2018

A paper printed September 27 in Scientific Reviews reveals the optimistic outcomes of a section II medical trial utilizing the oral remedy DFMO to stop relapse in youngsters with Excessive Danger Neuroblastoma (HRNB).

Neuroblastoma is a type of most cancers that develops from immature nerve cells present in a number of areas of the physique. It happens most frequently in infants and younger youngsters, normally beneath the age of 5. The illness stays a problem in pediatric oncology and present therapies embody therapies which have vital long-term unwanted effects for sufferers.

HRNB accounts for 15 % of all childhood most cancers deaths, partially, on account of the truth that almost half of all sufferers who attain remission will relapse.

“These outcomes are promising and have modified the outlook for our sufferers with excessive danger neuroblastoma,” mentioned Giselle Sholler, MD, director of pediatric oncology analysis at Spectrum Well being Helen DeVos Kids’s Hospital and principal investigator of the examine.

“By utilizing DFMO for 2 years after ending standard remedy, we have seen an general two-year survival fee for these youngsters of 97 %. This can be a giant enhance in survival,” Sholler added. “Beforehand it was believed that youngsters with refractory and relapsed neuroblastoma have been thought of incurable. This examine reveals greater than 50 % of sufferers remaining in remission as much as 4 years.”

Beat Childhood Most cancers’s trial studied using difluoromethylornithine (DFMO) as a single agent for enrolled sufferers at 20 youngsters’s hospitals from June 2012 to February 2016. The youngsters acquired two years of oral DFMO twice each day and have been evaluated for outcomes of occasion free survival (EFS*) and general survival (OS). The examine used focused oral remedy of an ODC inhibitor (DFMO), as a upkeep remedy to stop relapse in HRNB sufferers after normal remedy. DFMO works by focusing on particular most cancers stem cell pathways and “turning off” the cells, thereby stopping the most cancers from rising again.

There have been two arms on this examine, the primary designed for sufferers who had accomplished normal remedy, and the second for youngsters who have been capable of obtain remission after having beforehand relapsed. Each of those affected person populations are at very excessive danger of relapsing after finishing remedy and due to this fact could be superb candidates for utilizing a upkeep remedy with the aim of stopping relapse.

With a median observe up of three.5 years, the primary arm of the examine had 100 eligible sufferers. The outcomes present that two-year EFS was 84 % and two-year OS was 97 %.

With a median observe up of three.7 years, the examine enrolled 39 beforehand relapsed sufferers and the outcomes reported within the journal confirmed that two yr EFS was 54 % and two-year OS was 84 % for these youngsters who had beforehand relapsed.

“Whereas these EFS and OS figures at two years are exceptional, the actually thrilling a part of these outcomes is that EFS and OS are secure out to 4 years,” mentioned Patrick Lacey of Beat NB Most cancers Basis, one of many childhood most cancers parent-led foundations that funded this medical trial. “Not solely did this oral drug result in a protracted and secure remission for the youngsters on this examine, however the drug was extraordinarily protected and properly tolerated on this affected person inhabitants.”

“Whereas many youngsters have been capable of attain remission with the present, albeit harsh, upfront therapies, these remissions will not be traditionally sturdy,” Dr. Sholler added. “The present five-year survival curves haven’t modified considerably prior to now 20 years regardless of latest will increase in two-year survival because of intensified therapies and new multimodal therapies.”

Principal Investigator at MUSC, Jaqueline Kraveka, MD, states survival for youngsters with high-risk neuroblastoma stays a problem. “These outcomes are groundbreaking and really thrilling for oncologists and their affected person households. I’m thrilled to have our confirmatory examine open at so many websites throughout the USA and Canada, enabling youngsters to obtain this remedy near residence.”

Supply:

https://newsroom.spectrumhealth.org/study-finds-that-dfmo-increases-survival-for-children-with-high-risk-neuroblastoma/

Aspect Results of Excessive Blood Stress Medicine / ผลข้างเคียงของยารักษาโรคความดัน….

Posted in Vasotec on 27th April 2018